<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146519</url>
  </required_header>
  <id_info>
    <org_study_id>20171292</org_study_id>
    <nct_id>NCT04146519</nct_id>
  </id_info>
  <brief_title>Parkinson's Disease Therapy Using Cell Technology</brief_title>
  <official_title>Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belarusian Medical Academy of Post-Graduate Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Belarusian Medical Academy of Post-Graduate Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with Parkinson's disease using mesenchymal stem cells is a perspective&#xD;
      method to influence on the pathogenesis of the disease. At the same time, this is a complex&#xD;
      and still insufficiently explored process. Autologous mesenchymal stem cells will be&#xD;
      transplanted to 30 patients with Parkinson's disease. The results of the effectiveness of the&#xD;
      combined and intravenous routes of mesenchymal stem cells administration on the motor and&#xD;
      non-motor symptoms in these patients will be evaluated and compared with the results of&#xD;
      control group that received placebo therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>motor symptoms change</measure>
    <time_frame>3 month</time_frame>
    <description>Positive trend is going to be detected in the overall score of the third part of the UPDRS scale(Unified Parkinson Disease Rating Scale) in the off- and in the on-period:neurological examination of patients in the dynamics is carried out in the morning after a 12 (24) - hour break in taking anti-Parkinsonian drugs &quot;off-state&quot;, then one hour after they were taken &quot;on-state&quot;.&#xD;
A score of 64 on the third part of the UPDRS scale represents the worst (total motor disability) with a score of zero representing (no disability).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>non-motor symptoms change</measure>
    <time_frame>3 month</time_frame>
    <description>Identification and assessment of the severity of non-motor symptoms is carried out using Non-motor Symptoms Questionnaire (PD NMS Questionnaire).A score of 30 represents the worst result with a score of zero representing (no disability).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sleep quality change</measure>
    <time_frame>3 month</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) is used to assess sleep quality over the last month.The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>daytime sleepiness change</measure>
    <time_frame>3 month</time_frame>
    <description>The Epworth Sleepiness Scale (ESS) is used to measure daytime sleepiness.The ESS score can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>signs of depression change</measure>
    <time_frame>3 month</time_frame>
    <description>We use the Hamilton Depression Scale - Hamilton psychiatric rating scale for depression (HDRS) - to identify signs of depression. A score of 52 represents the worst result with a score of zero representing (no disability).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Transplantation:Mesenchymal Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous MMSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous mesenchymal stem cells</intervention_name>
    <description>Autologous mesenchymal stem cells</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A reliable diagnosis of Parkinson's disease, according to the diagnostic criteria&#xD;
             developed by the Brain Bank of the Society for Parkinson's disease of Great Britain&#xD;
             (UK Brain Bank Criteria, 1992).&#xD;
&#xD;
          2. Stage of the disease according to Hen-Yar: 1.5 - 3.0 stage.&#xD;
&#xD;
          3. Rapidly progressive type with a change in the stages of Parkinson's disease in no more&#xD;
             than 4 years.&#xD;
&#xD;
          4. A good response to levodopa treatment: a positive dopamine test for assessing motor&#xD;
             functions by a total score of section 3 of the UPDRS scale in the on- and off-period&#xD;
             (not less than 30%).&#xD;
&#xD;
          5. The duration of the disease is not more than 8 years with the absence of motor&#xD;
             fluctuations and dyskinesias.&#xD;
&#xD;
          6. The age of patients is up to 65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        e and parkinsonism-plus. 2. Severe concomitant diseases (congestive heart failure,&#xD;
        myocardial infarction, pneumonia, decompensated diabetes mellitus, cachexia, etc.).&#xD;
&#xD;
        3. Autoimmune diseases, a tendency to bleeding, a history of sepsis. 4. Oncological&#xD;
        diseases. 5. The presence of acute or exacerbation of the chronic inflammatory process of&#xD;
        the sinuses or oral cavity.&#xD;
&#xD;
        6. A positive result for HIV, hepatitis B (HBV), hepatitis C (HCV), syphilis (RW).&#xD;
&#xD;
        7. Cognitive deficit. 8. Mental disorders - hallucinations, behavior disorders. 9.&#xD;
        Depression of a pronounced degree (not more than 19 points on the Hamilton scale).&#xD;
&#xD;
        10. Alcoholism, drug addiction, criminal liability in the patient's history. 11. Pregnancy,&#xD;
        lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vladimir Ponomarev, PhD</last_name>
    <phone>80172959016</phone>
    <email>professor.ponomarev@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Belarusian Medical Academy of Postgraduate Education</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Ponomarev, PhD</last_name>
      <phone>80172959016</phone>
      <email>professor.ponomarev@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <reference>
    <citation>Boika A, Aleinikava N, Chyzhyk V, Zafranskaya M, Nizheharodava D, Ponomarev V. Mesenchymal stem cells in Parkinson's disease: Motor and nonmotor symptoms in the early posttransplant period. Surg Neurol Int. 2020 Nov 11;11:380. doi: 10.25259/SNI_233_2020. eCollection 2020.</citation>
    <PMID>33408914</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>February 27, 2021</last_update_submitted>
  <last_update_submitted_qc>February 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>intranasal transplantation</keyword>
  <keyword>intravenous transplantation</keyword>
  <keyword>tandem transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

